<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527577</url>
  </required_header>
  <id_info>
    <org_study_id>0908127</org_study_id>
    <secondary_id>2009-017768-18</secondary_id>
    <secondary_id>A100140-28</secondary_id>
    <nct_id>NCT02527577</nct_id>
  </id_info>
  <brief_title>Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.</brief_title>
  <acronym>BLOC-TAP</acronym>
  <official_title>Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The indications liver cancer surgery currently booming due to the increase in surgical
      techniques and instruments for a more secure resection of liver tissue with a significant
      reduction in bleeding or surgical complications. This allowed to expand surgical indications
      in the most fragile patients so assuming optimized anesthetic care.

      So far, the technique of analgesia reference to this surgery remains administration of
      morphine analgesia via a device controlled by the patient (PCA) for epidural analgesia is
      against-indicated because of induced bleeding disorders by surgery.

      Rafi then McDonnell in 2007 have described a new technique of loco regional anesthesia, the
      abdomen of the Transversus Abdominis Plane (TAP) nerve block(TAP), which allows selective
      anesthesia of the abdominal wall. But parietal pain related muscular and nervous sagging
      surgical approach represent a significant share of post operative pain.

      This study proposes an evaluation of the abdomen transverse blocks in hepatectomy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulties to recruit patients
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>consumption of morphine over the first 48 hours postoperative.</measure>
    <time_frame>at 48 hours postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic of ropivacaine (plasma concentrations)</measure>
    <time_frame>1, 2, 3, 6, 10, 24, 36, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Liver Cancer, Adult</condition>
  <arm_group>
    <arm_group_label>ropivacaïne chlorhydrate monohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RopivacaIne chlorhydrate</intervention_name>
    <description>3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48</description>
    <arm_group_label>ropivacaïne chlorhydrate monohydrate</arm_group_label>
    <other_name>3mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>injection Hour (H) 0, H12 ; H24, H36 ; H48</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hepatectomy or segmentectomy

        Exclusion Criteria:

          -  Sepsis uncontrolled current

          -  Overdose in anticoagulant during general anesthesia

          -  Thrombocytopenia &lt;50 g / dl

          -  Severe renal impairment: Cockcroft &lt;30 ml / min

          -  history of ventricular arrhythmia serious unexplained .*

          -  Allergy to local anesthetics of the amide

          -  Contraindication to remifentanil and morphine

          -  Hypovolemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>carine.labruyere@chu-st-etienne.fr MOLLIEX, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

